Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.

Name: Αlpha¹ Rigor Record — Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.
Item: Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.
Rating: 59
Author: Αlpha¹

Kapulu MC, Orenge F, Kimani D, Kibwana E, Kibet H, Mutahi M, Datoo MS, Bellamy D, Musembi J, Ngoto O, Rashid H, Akinyi S, Mwatasa MH, Nyamako L, Keter K, Gatheru R, Mutiso A, Musyoki J, Mwacharo J, Abebe Y, James ER, Billingsley PF, Ngetsa C, Mosobo M, Makale J, Tawa B, Wamae K, Ochola-Oyier LI, Lawrie A, Ramos-Lopez F, Roberts R, Richie TL, Sim BKL, Hoffman SL, Ewer KJ, Hill AVS, Hamaluba M, Bejon P

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2★ (Weak), 0 critical, 6 high issues for “Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 18 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced7 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions4

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2b randomized controlled human challenge trial with strong ethical approvals, clear reporting of demographics, and a concrete data availability statement. The main weaknesses are the small sample size (especially the DVI R21 group, n=5), the power analysis not matching actual group sizes, and imprecise reporting of p-values as thresholds rather than exact values.

All three reviewers classified the study as interventional; no disagreement. The evaluation covered the full text, including methods, results, and supplementary information. Not applicable criteria (e.g., cell line authentication, housing conditions) were excluded. The statistics verification component recomputed only a subset of tests (6 total, 4 consistent, 2 inconsistent but not decision errors); this does not constitute a full validation of all statistical results.

9 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 2 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 2 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior vaccine efficacy trials (RTS,S/AS01, R21/Matrix-M), animal model evidence that dermal sporozoites are more readily blocked, and notes the lack of human CHMI studies comparing ID vs DVI. The hypothesis follows logically from this evidence. Limitations of prior research (e.g., noise from mixed inoculation routes in mosquito bites) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific premise, citing prior work on anti-CSP antibodies, animal models showing route-dependent protection, and the gap in human CHMI studies.

Evidence

direct quote[Main, paragraph 1-3]

“Furthermore, in animal models, dermal sporozoites are more readily blocked by anti-CSP antibodies compared to intravenous sporozoites”